Amsterdam, October 1st / PRNewswire / -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA) today announced a partnership with Cradle. Hansa Biopharma is a pioneer company focused on the treatment of rare IgG-related immune diseases; Cradle has built a leading AI motor protein design and engineering platform for biologics.
Hansa will utilize Cradle's end-to-end platform throughout its entire R&D process to design, optimize, and advance new therapeutic candidates. Both parties stated that with the help of Cradle's AI motor protein engineering platform, the goal is to accelerate the development of new therapies for patients suffering from severe autoimmune diseases.
The main product of Hansa, imlifidase, is a pioneering enzyme that has already been commercially sold in Europe under the brand Idefirix. It is currently undergoing review by the US regulatory authorities FDA with a PDUFA scheduled for December. This product is suitable for highly sensitized patients awaiting kidney transplantation.
Hansa, the person in charge of research and early development, Sofia J and rnum stated: "We evaluated various AI models and suppliers, and ultimately chose Cradle because it possesses three capabilities that we believe are crucial for the next generation of protein engineering: end-to-end support covering the entire R&D process from hit identification; multi-parameter optimization for complex engineering goals; and active learning using our own data to drive increasingly predictable results. Each of these capabilities can accelerate our laboratory's closed-loop process. The platform of Cradle enables Hansa scientists to design and engineer better therapeutic candidates faster and with more confidence."
The company stated that this collaboration reflects Hansa's ongoing strategic investment in AI driven drug discovery. As they extend the application of AI to new research and development projects, it is also part of their effort to build the next generation of pipeline. Hansa mentioned that Cradle has already achieved results in collaborating with leading biopharmaceutical companies, making them a natural partner. Both parties believe that this also reflects the industry's growing shift towards unified AI platforms, which integrate candidate generation, optimization, and continuous learning from experimental data into a single workflow. Cradle indicated that their clients can see a reduction in development cycles of up to 18 months, which means that the research and development costs for each clinical candidate may be significantly lowered.
Cradle CEO and Co-Founder Stef van Grieken stated: "The future of multimodal therapy engineering is not about investing more AI computing power or juggling between a bunch of models, but about empowering scientists to use a platform that can learn with them, while allowing them to apply their unique human expertise to solve complex molecular challenges quickly and accurately on a scaled-up basis. We are delighted to collaborate with Hansa to help accelerate the discovery and development of new, high-quality therapies for patients with rare and severe autoimmune diseases."
About Hansa Biopharma
Hansa Biopharma AB is a pioneer biopharmaceutical company in the commercialization phase, dedicated to developing and commercializing novel immunomodulatory therapies to improve the treatment of patients with acute or complex immune diseases. The company's proprietary IgG cleavage enzyme technology platform addresses significant unmet medical needs in transplantation, gene therapy, and autoimmune diseases. Its product portfolio includes imlifidase, a novel immunoglobulin G (IgG) antibody cleavage enzyme therapy that has been proven to help highly sensitized patients undergo kidney transplants; as well as HNSA-5487, a next-generation IgG cleavage molecule that will be used for the development of treatments for Guillain-Barré syndrome (GBS). Hansa Biopharma is headquartered in Lund, Sweden, and has operations in Europe and the United States. The company is listed on NASDAQ Stockholm with the stock code HNSA. For more information, please visit www.hansabiopharma.com and follow its LinkedIn.
©2026 Hansa Biopharma AB. Hansa Biopharma, beacon, logo, IDEFIRIX, IDEFIRIX, flower, and logo are all trademarks of Lund, Sweden. All rights reserved.
About Cradle
The mission of Cradle is to help every scientist turn what seems impossible today in terms of therapies, foods, and materials into the norm of tomorrow. Cradle's end-to-end protein engineering platform assists scientists in consciously engineering biologics throughout the entire lifecycle, from design to candidate development. It integrates AI-driven molecular engineering, experiment data-based active learning, and multi-property optimization into a single system. Today, this platform is trusted by numerous large pharmaceutical, industrial biotechnology, agricultural, and consumer goods companies around the world, covering over 80 active research and development projects. Cradle is headquartered in Amsterdam, Netherlands; Zurich, Switzerland; and the United States. Its team consists of experts in machine learning and biotechnology research, with extensive industry experience from several leading global technology and biotech companies. Cradle has received support from IVP as well as Index Ventures and Kindred Capital. For more information, please visit cradle.bio.
